Spots Global Cancer Trial Database for nexavar
Every month we try and update this database with for nexavar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy | NCT01539681 | Hepatocellular ... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | NCT01171651 | Carcinoma, Hepa... | JX-594 followed... | 18 Years - | SillaJen, Inc. | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer | NCT00619996 | Prostate Cancer | Sorafenib (Nexa... Docetaxel | - | Italian Trial in Medical Oncology | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma | |
| A Study of Radiation With Sorafenib in Advanced Cancer | NCT00610246 | Cancer | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | NCT00844883 | Hepatocellular ... Hepatoma | sorafenib LC Bead-TACE | 18 Years - | Yale University | |
| Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) | NCT01337492 | Carcinoma, Hepa... | Nexavar | 18 Years - | Case Comprehensive Cancer Center | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer | NCT00825734 | Metastatic Brea... | Sorafenib Ixabepilone | 18 Years - | SCRI Development Innovations, LLC | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | NCT00956436 | Hepatocellular ... | BIIB022 Sorafenib | 18 Years - | Biogen | |
| Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | NCT01507740 | Hepatocellular ... Non-small Cell ... Renal Cell Canc... Colorectal Canc... | Avastin Suntent Nexavar | 18 Years - | Medical University Innsbruck | |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | NCT01411436 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Radiation With Sorafenib in Advanced Cancer | NCT00610246 | Cancer | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | NCT02196857 | Leukemia | Azacytidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program | NCT01412671 | Carcinoma, Rena... | Sorafenib (Nexa... | - | Bayer | |
| Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer | NCT00525161 | Breast Cancer | sorafenib | 18 Years - | University of Kentucky | |
| A Study of Radiation With Sorafenib in Advanced Cancer | NCT00610246 | Cancer | Sorafenib | 18 Years - | University Health Network, Toronto | |
| Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) | NCT00586105 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Trial of TRC105 and Sorafenib in Patients With HCC | NCT02560779 | Hepatocellular ... | Carotuximab (TR... Sorafenib | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy | NCT01539681 | Hepatocellular ... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | NCT01197170 | Solid Tumors Advanced Cancer | Anastrozole Bevacizumab Everolimus Sorafenib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | NCT00956436 | Hepatocellular ... | BIIB022 Sorafenib | 18 Years - | Biogen | |
| Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer | NCT00619996 | Prostate Cancer | Sorafenib (Nexa... Docetaxel | - | Italian Trial in Medical Oncology | |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | NCT03565536 | Thyroid Cancer,... | Nexavar operation External radiat... | 18 Years - | Fujian Medical University | |
| Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program | NCT01412671 | Carcinoma, Rena... | Sorafenib (Nexa... | - | Bayer | |
| Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | NCT01507740 | Hepatocellular ... Non-small Cell ... Renal Cell Canc... Colorectal Canc... | Avastin Suntent Nexavar | 18 Years - | Medical University Innsbruck | |
| Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | NCT01507740 | Hepatocellular ... Non-small Cell ... Renal Cell Canc... Colorectal Canc... | Avastin Suntent Nexavar | 18 Years - | Medical University Innsbruck | |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | NCT01411436 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer | |
| Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | NCT01254890 | Leukemia | Azacitidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | NCT03565536 | Thyroid Cancer,... | Nexavar operation External radiat... | 18 Years - | Fujian Medical University | |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | NCT00498836 | Malignant Melan... | CP-4055 Sorafenib (Nexa... | 18 Years - | Clavis Pharma | |
| Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | NCT01618253 | Hepatocellular ... Hepatocellular ... Hepatoma Liver Cancer | Sorafenib Conventional fr... | 18 Years - 80 Years | Medical College of Wisconsin | |
| Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma | NCT01982097 | Carcinoma, Rena... | Sorafenib (Nexa... | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
